Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy (2018)
Sequence: GRKKRRQRRRQC
| Experiment Id | EXP002551 |
|---|---|
| Paper | Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy |
| Peptide | HIV TAT-Cys |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 5 µM TAT-PEG-SN38 |
| Rna Concentration | 100 nM |
| Mixing Ratio | protamine:siRNA = 1:0.3 (w/w) |
| Formulation Format | Transferrin-targeted liposomes |
| Formulation Components | SPC/cholesterol/TAT-PEG-SN38/protamine/siRNA/DSPE-PEG-Tf |
| Size Nm | 148.00 |
| Zeta Mv | 7.80 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa |
| Animal Model | |
| Administration Route | |
| Output Type | Survivin protein knockdown, cytotoxicity, apoptosis |
| Output Value | Strong survivin knockdown; IC50 = 175 nM (Tf-L-SN38/P/siRNA) |
| Output Units | |
| Output Notes | Confocal + FACS uptake; Western blot survivin suppression; apoptosis induction |
| Toxicity Notes | Enhanced cytotoxicity vs controls due to siRNA codelivery |
| Curation Notes |